Compare MASS & NSPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MASS | NSPR |
|---|---|---|
| Founded | 2012 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 324.4M | 81.8M |
| IPO Year | 2020 | N/A |
| Metric | MASS | NSPR |
|---|---|---|
| Price | $5.96 | $1.93 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 2 |
| Target Price | ★ $9.00 | $4.50 |
| AVG Volume (30 Days) | ★ 361.8K | 101.4K |
| Earning Date | 11-10-2025 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $65,045,000.00 | $7,779,000.00 |
| Revenue This Year | N/A | $22.76 |
| Revenue Next Year | $19.55 | $75.45 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 36.21 | 14.04 |
| 52 Week Low | $1.81 | $1.59 |
| 52 Week High | $9.34 | $3.80 |
| Indicator | MASS | NSPR |
|---|---|---|
| Relative Strength Index (RSI) | 39.13 | 48.80 |
| Support Level | $6.26 | $1.74 |
| Resistance Level | $6.83 | $2.00 |
| Average True Range (ATR) | 0.39 | 0.12 |
| MACD | 0.07 | 0.01 |
| Stochastic Oscillator | 7.94 | 53.85 |
908 Devices Inc manufactures medical devices. It has developed a suite of purpose-built handheld and desktop mass spectrometry, or Mass Spec, devices for the point-of-need. Mass Spec devices are used at the point-of-need to interrogate unknown and invisible materials and provide quick, actionable answers to directly address some of the critical problems in life sciences research, bioprocessing, industrial biotech, forensics, and adjacent markets. The company geographically derives maximum revenue from United States, and also has its presence in Europe, Middle East and Africa, Americas and Other and Asia Pacific.
InspireMD Inc is a United States based medical device company. It is focused on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of complex vascular and coronary disease. The products of the company are the CGuard carotid Embolic Prevention System (CGuard EPS) and the MGuard Prime Embolic Protection System (MGuard Prime EPS). It generates the majority of the revenue from the sales of CGuard EPS which combines MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. The group operates in Italy, Germany, Russia and other countries.